ALECT2 amyloidosis

ALECT2 amyloidosis is a rare form of amyloidosis where a protein called leukocyte chemotactic factor-2 (LECT2) builds up in body tissues. This protein deposition mainly affects the kidneys, leading to signs of chronic kidney problems. Over time, these deposits in the kidney’s cortical interstitium, tubular basement membranes, glomeruli, and vessel walls can impair kidney function. Beyond the kidneys, amyloid deposits may also occur in other organs such as the liver, lungs, spleen, and adrenal glands. This distribution can contribute to the overall impact on a person’s health. The condition usually progresses slowly, eventually leading to issues such as proteinuria, high blood pressure, and reduced kidney function.

People with ALECT2 amyloidosis may notice signs related to kidney problems, including proteinuria (protein in the urine), high blood pressure, and decreased kidney function. As the condition advances, these symptoms can progress and lead to kidney failure.

In ALECT2 amyloidosis, the buildup of LECT2 protein in various tissues is the key factor. There is no known genetic mutation or cause directly linked to this condition. The exact reasons why the LECT2 protein misfolds and deposits in tissues remain unclear.

Information about treatment is currently limited for this condition.

ALECT2 amyloidosis usually shows a slow progression, especially in the kidneys, which can lead to gradually worsening kidney function and eventual kidney failure. The overall outlook may vary, and the condition can have a significant impact on quality of life as kidney function declines.

Information about research is currently limited for this condition.